
    
      The study is a Phase I, prospective, three cohort, open label study conducted on one cohort
      of non-atopic subjects and two cohorts of patients with a history of allergic rhinitis
      symptoms to Japanese red cedar Cry j 2 pollen allergen. The study will be conducted at 1
      study center. Subjects are enrolled in the trial for a period of 72 days. The objectives of
      the statistical analyses are to establish the safety and to explore the immunogenicity of the
      LAMP-vax vaccine. All statistical analyses conducted on the data from this trial will be
      exploratory in nature.
    
  